Projecting future complications of chronic hepatitis C in the United States

被引:443
作者
Davis, GL
Albright, JE
Cook, SF
Rosenberg, DM
机构
[1] Baylor Univ, Ctr Med, Baylor Reg Transplant Inst, Div Hepatol, Dallas, TX 75246 USA
[2] GlaxoSmithKline, Res Triangle Pk, NC USA
关键词
VIRUS-INFECTION; COST-EFFECTIVENESS; INITIAL TREATMENT; INTERFERON-ALPHA; PLUS RIBAVIRIN; LIVER FIBROSIS; BLOOD-DONORS; RISK-FACTORS; NON-A; PROGRESSION;
D O I
10.1053/jlts.2003.50073
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Chronic hepatitis C virus (HCV) infection is common and often results in slowly progressive liver disease. Although acute hepatitis C is now uncommon, most patients with acute infection have developed chronic hepatitis, and, therefore, the pool of infected patients is large. We used a modification of a previously described natural history model for HCV infection to project the number of cases of HCV infection, cirrhosis, and liver failure over the next 40 years. The model estimated the prevalence of HCV infection in the United States was 3.07 X 10(6) in 1993 (compared with an adjusted National Health and Nutrition Evaluation Survey (NHANES) III estimate of 2.8 to 3.5 X 10(6)). A gradual decline in the prevalence of infection should occur by year 2040 because of aging and natural deaths among the infected pool. However, as the duration of infection increases in the surviving cohort, the proportion with cirrhosis will increase from 16% to 32% by 2020 in an untreated population. Complications of cirrhosis also will increase dramatically over the next 20 years: hepatic decompensation (up 106%), hepatocellular carcinoma (up 81%), and liver-related deaths (up 180%). Although current treatment regimens eradicate HCV in over 50% of cases, many more patients would need to be treated to significantly impact disease progression. Identification and treatment of every case of HCV infection (with or without cirrhosis) would reduce the number of cases of decompensated cirrhosis by almost half after 20 years. Despite the declining incidence of acute HCV infection, chronic hepatitis C is common. The prevalence of cirrhosis and the incidence of its complications will increase over the next 10 to 20 years, because the duration of infection increases among those with chronic hepatitis C. These data emphasize the need for greater access to transplantation by expansion of the donor pool, increasing use of split livers and living donors, and novel options such as xenotransplantation.
引用
收藏
页码:331 / 338
页数:8
相关论文
共 42 条
  • [1] HEPATITIS-C VIRUS AMONG BLOOD-DONORS - FOLLOW-UP-STUDY
    ALONSO, C
    PEDROSO, ML
    DESANJOSE, S
    MONTCHARMONT, P
    CHEVRE, JM
    BOUCAUD, MJ
    LAMBERT, V
    CORTEY, ML
    TREPO, C
    [J]. TRANSFUSION, 1994, 34 (06) : 527 - 530
  • [2] Alter M J, 1997, Clin Liver Dis, V1, P559, DOI 10.1016/S1089-3261(05)70321-4
  • [3] The prevalence of hepatitis C virus infection in the United States, 1988 through 1994
    Alter, MJ
    Kruszon-Moran, D
    Nainan, OV
    McQuillan, GM
    Gao, FX
    Moyer, LA
    Kaslow, RA
    Margolis, HS
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (08) : 556 - 562
  • [4] RISK-FACTORS FOR ACUTE NON-A, NON-B HEPATITIS IN THE UNITED-STATES AND ASSOCIATION WITH HEPATITIS-C VIRUS-INFECTION
    ALTER, MJ
    HADLER, SC
    JUDSON, FN
    MARES, A
    ALEXANDER, WJ
    HU, PY
    MILLER, JK
    MOYER, LA
    FIELDS, HA
    BRADLEY, DW
    MARGOLIS, HS
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1990, 264 (17): : 2231 - 2235
  • [5] [Anonymous], 1998, MMWR Recomm Rep, V47, P1
  • [6] BARRERA JM, 1995, HEPATOLOGY, V21, P639, DOI 10.1002/hep.1840210306
  • [7] Belle S H, 1996, Clin Transpl, P15
  • [8] Modeling therapeutic benefit in the midst of uncertainty - Therapy for hepatitis C
    Bennett, WG
    Pauker, SG
    Davis, GL
    Wong, JB
    [J]. DIGESTIVE DISEASES AND SCIENCES, 1996, 41 (12) : S56 - S62
  • [9] Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C
    Bennett, WG
    Inoue, Y
    Beck, JR
    Wong, JB
    Pauker, SG
    Davis, GL
    [J]. ANNALS OF INTERNAL MEDICINE, 1997, 127 (10) : 855 - +
  • [10] Health care costs of a continuing epidemic of hepatitis C virus infection among injecting drug users
    Brown, K
    Crofts, N
    [J]. AUSTRALIAN AND NEW ZEALAND JOURNAL OF PUBLIC HEALTH, 1998, 22 (03) : 384 - 388